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ABSTRACT
Background: Prostate cancer is the commonest cancer among men in Nigeria and early detection is key to cure 
and survival but its screening through prostate specific antigen (PSA) has remain controversial in literature. 
Screening with prostate specific antigen (PSA) has led to more men diagnosed with prostate cancer than in 
previous years with potential for negative effects from overdiagnosis and overtreatment. 
Method: This is a review article on the controversies and recommendations regarding prostate cancer screening 
following detailed search of literature and online databases such as Pubmed and Google using PSA, DRE, 
prostate cancer, screening as key words.  
Conclusion: Prostate cancer screening is fraught with a lot of controversies therefore it should be individualised 
through discussion between the physician and informed client using appropriate guidelines and 
recommendations.  
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Introduction
Prostate Cancer is the number one cancer in men with 
increasing incidence and morbidity among black 
1,2African ancestry . The worldwide burden of this 
3disease is rising .  Cure is possible through early 
detection from screening, but it is not clear whether 
early detection and treatment lead to any change in 
4the natural history and outcome of the disease . The 
goal of prostate cancer screening is to reduce the 
morbidity and mortality from this disease through 
early detection. However it has been fraught with 
controversies in many literatures and this has led to 
heated discussions and debates resulting in many 
5conflicting positions and policy papers . 
Screening is the presumptive identification of 
unrecognized disease or defects by means of tests, 
examinations, or other procedures that can be applied 
6rapidly . Common screening techniques for prostate 
cancer include the digital rectal examination (DRE) 
and assessment of serum prostate-specific antigen 
7(PSA) levels .
DRE is the oldest and cheapest. It was the first and 
only diagnostic tool used for detection of prostate 
cancer until the mid-1980 before the discovery of 
8PSA . However, this test has considerable 
interexaminer variability and the majority of cancers 
detected by means of digital rectal examination are at 
9,10an advanced stage . 
The use of PSA as a serum marker has revolutionised 
prostate cancer diagnosis but its use for screening is 
controversial. PSA is organ- but not cancer specific, 
therefore, it may be elevated in benign prostatic 
hyperplasia (BPH), prostatitis and other non-
malignant condition. 
Controversies Screening generally aims to reduce 
disease-specific and overall mortality, and to improve 
a person's future quality of life. Screening for prostate 
cancer has generated considerable debate within the 
medical and broader community, as demonstrated in 
literature and the varying recommendations made by 




A number of studies have demonstrated the 
benefits of prostate cancer screening. The European 
Randomized Study of Screening for Prostate Cancer 
(ERSPC) found that PSA screening significantly 
reduces the mortality of prostate cancer but is also 
associated with a high risk of over-diagnosis.
Furthermore, data from the ERSPC, showed the 
cumulative risk of metastatic disease at 9 to 11 years 
of follow-up was 31% to 33% lower in the screened 
 
arm compared to the control arm and that the benefit 
13,14
of screening increases with time . Reduction in 
prostate cancer-specific mortality may take up to 10 
years, therefore, men who have a life expectancy less 
than 10 should be informed that screening for prostate 
15
cancer is unlikely to be beneficial .
The incidence of metastatic disease at presentation 
has declined by approximately three-fourths in the 
15
US since the advent of PSA screening . 
The ERSPC report was consistent with the Göteborg 
randomised population-based prostate-cancer 
screening trial which demonstrated a 56% reduction 
in risk of metastatic disease and that the benefit of 
prostate-cancer screening compares favourably to 
16
other cancer screening programs .
These results however are in contrast with the US 
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Prostate, Lung, Colorectal and Ovarian (PLCO) 
Cancer Screening trial conducted in the United 
States. The PLCO studied the mortality of prostate, 
lung, cervix, and ovary cancer screening in a 
randomised fashion. The PLCO study showed no 
mortality differences between its randomised arms 
17
for prostate cancer after seven years of follow-up . 
After 13 years of follow-up, the cumulative mortality 
rates from prostate cancer in the intervention and 
control groups were 3.7 and 3.4 deaths per 10,000 
person-years, respectively, meaning that there was no 
17
significant difference between the two groups . 
In a study by Bangma and colleagues, it showed that 
the main drawback of prostate cancer screening is the 
increased risk of overdiagnosis of prostate cancer 
meaning detection of cancers that may not give rise to 
symptoms or lead to death during the lifetime of a 
18
typical man . This was consistent with the 
conclusion made in the systematic review of article 
11
according to the Cochrane database system  which 
showed that over diagnosis and over treatment are 
common and are associated with treatment-related 
harms and that men should be informed of these and 
the demonstrated adverse effects when they are 




Based on the results of the PLCO trial, the U.S. 
Preventive Service Task Force (USPSTF) advised 
against PSA screening in their draft recommendation 
19
issued in 2011 . However, many large national 
urological associations like the American Urological 
Association (AUA), Canadian Urological 
Association (CUA) and European Urological 
Association (EAU) still value the benefit of PSA 
screening for men after age 45 to 50 and recommend 
physician-patient discussion about screening on an 
individual basis. The decision should follow a 
discussion about the uncertainties, risks, and 
potential benefits of screening with age of patient, 
patients` risk factor and life expectancy taken into 
4,11,15
consideration .
Currently, active surveillance for early detected cases 
is a feasible strategy to reduce overtreatment without 
compromising the therapeutic window and chance 
for cure. The review of literature showed that active 
surveillance can reduce overtreatment by almost 50 
percent at 15 years and that men on active 
surveillance are not at immediate risk of death from 




The topic of prostate cancer screening is 
controversial in many literature. It is useful in early 
detection of prostate cancer but with the risk of 
overdiagnosis and overtreatment. Many national 
urological associations (AUA, EUA, CUA) still find 
it valuable provided it is individualised and done 
through discussion between the physician and 
informed client using appropriate guidelines and 
recommendations. 
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